ICT-107

Drug Overview

ICT-107 (ImmunoCellular Therapeutics) is an autologous dendritic cell immunotherapy that targets six different antigens associated with glioblastoma multiforme (GBM). By targeting multiple biomarkers, ICT-107 overcomes the tumor escape mechanisms commonly associated with single antigen targeting. Additionally, the therapy targets biomarkers found on cancer stem cells, which are believed to be a key contributor to the proliferation and recurrence of tumors. ICT-107, in combination with chemoradiation, is in development for the treatment of human leukocyte antigen A serotype 2 (HLA-A2)-positive GBM following tumor resection.

Analyst Outlook

ICT-107 (ImmunoCellular Therapeutics) is a promising targeted and personalized cancer vaccine, but is expected to reach the market years after its closest competitor DCVax-L (Northwest Biotherapeutics), which has demonstrated similar survival data. However, the specificity of ICT-107’s Phase III trial design may provide it with an advantage over its competitor. The study will focus on human leukocyte antigen A2 (HLA-A2)-positive glioblastoma multiforme (GBM) patients and will stratify outcomes based on patients’ O-6-methylguanine DNA methyltransferase (MGMT) methylation status. This could assist in displaying value in a particular treatment setting and improve its chances for reimbursement in cost-conservative markets. Nonetheless, Datamonitor Healthcare anticipates that ImmunoCellular Therapeutics will be forced to give ICT-107 a premium price to recoup manufacturing costs, limiting the drug’s commercial potential.